Vera Therapeutics, Inc. beat EPS estimates 25% of the time across 16 reported quarters (4 beats, 12 misses), averaging -10.7% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-1.60 | $-1.52 | +5.0% | Beat | |
| Q1 FY26 | $-1.26 | $-1.69 | -34.1% | Miss | |
| Q4 FY25 | $-1.34 | $-1.39 | -3.7% | Miss | |
| Q3 FY25 | $-1.20 | $-1.26 | -5.0% | Miss | |
| Q2 FY25 | $-0.82 | $-1.20 | -46.3% | Miss | |
| Q1 FY25 | $-0.75 | $-0.81 | -8.0% | Miss | |
| Q4 FY24 | $-0.83 | $-0.72 | +13.3% | Beat | |
| Q3 FY24 | $-0.69 | $-0.85 | -23.2% | Miss | |
| Q2 FY24 | $-0.58 | $-0.62 | -6.9% | Miss | |
| Q1 FY24 | $-0.53 | $-0.56 | -5.7% | Miss | |
| Q4 FY23 | $-0.53 | $-0.58 | -9.4% | Miss | |
| Q3 FY23 | $-0.50 | $-0.45 | +10.0% | Beat |
Back to VERA overview · VERA holders · VERA KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.